Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept [Yahoo! Finance]
Opthea Limited - American Depositary Shares (OPT)
Company Research
Source: Yahoo! Finance
Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 COAST and ShORe top-line results expected by mid-2025 MELBOURNE, Australia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD). The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe. Enrollment in ShORe is expected to be completed in calendar Q2 2024. Opthea intends to report topline results from these two trials by mid-2025. “Completion of patient enrollment in our first pivotal trial marks an imp
Show less
Read more
Impact Snapshot
Event Time:
OPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPT alerts
High impacting Opthea Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OPT
News
- Opthea to Present at the OIS Retina Innovation Summit at ARVO [Yahoo! Finance]Yahoo! Finance
- Opthea to Present at the OIS Retina Innovation Summit at ARVOGlobeNewswire
- Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT), [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints John Han, PharmD, as VP Medical Affairs [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints John Han, PharmD, as VP Medical AffairsGlobeNewswire
OPT
Sec Filings
- 4/25/24 - Form 6-K
- 4/9/24 - Form 6-K
- 4/5/24 - Form 6-K
- OPT's page on the SEC website